Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis - PubMed

Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis

S Kantengwa et al. J Neuroimmunol. 2007 Apr.

Abstract

We investigated whether glatiramer acetate (GA) treatment may affect Th1 differentiation at various T-cell maturation stages. Specifically, we analyzed the effect of in vivo GA treatment on intracellular synthesis of IL-2 and TNF-alpha by naive, memory and effector CD4(+) and CD8(+) T cells by five-colour flow cytometry. Our data indicate that GA treatment downregulates/normalizes an accelerated Th1 differentiation of CD4(+) T cells in RRMS patients at all stages of T-cell maturation. Most notably, we conclude that, by altering naive, unprimed CD4(+) T cells, GA treatment appears to affect T-cell differentiation, at least in part, in an antigen-independent manner.

Similar articles

• Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.

  Fellay B, Chofflon M, Juillard C, Paunier AM, Landis T, Roth S, Gougeon ML. Fellay B, et al. Immunology. 2001 Dec;104(4):383-91. doi: 10.1046/j.1365-2567.2001.01322.x. Immunology. 2001. PMID: 11899423 Free PMC article.

• Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.

  Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ. Biegler BW, et al. J Neuroimmunol. 2006 Nov;180(1-2):159-71. doi: 10.1016/j.jneuroim.2006.07.015. Epub 2006 Aug 28. J Neuroimmunol. 2006. PMID: 16935352 Clinical Trial.

• Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate.

  Rieks M, Hoffmann V, Aktas O, Juschka M, Spitzer I, Brune N, Schimrigk S, Przuntek H, Pöhlau D. Rieks M, et al. Eur Neurol. 2003;50(4):200-6. doi: 10.1159/000073860. Eur Neurol. 2003. PMID: 14634263

• Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

  Weber MS, Hohlfeld R, Zamvil SS. Weber MS, et al. Neurotherapeutics. 2007 Oct;4(4):647-53. doi: 10.1016/j.nurt.2007.08.002. Neurotherapeutics. 2007. PMID: 17920545 Free PMC article. Review.

• Glatiramer acetate: mechanisms of action in multiple sclerosis.

  Schrempf W, Ziemssen T. Schrempf W, et al. Autoimmun Rev. 2007 Aug;6(7):469-75. doi: 10.1016/j.autrev.2007.02.003. Epub 2007 Mar 6. Autoimmun Rev. 2007. PMID: 17643935 Review.

Cited by

• Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.

  Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, Chofflon M, Zamvil SS, Lalive PH. Burger D, et al. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4355-9. doi: 10.1073/pnas.0812183106. Epub 2009 Mar 2. Proc Natl Acad Sci U S A. 2009. PMID: 19255448 Free PMC article.

• The Evolving Mechanisms of Action of Glatiramer Acetate.

  Prod'homme T, Zamvil SS. Prod'homme T, et al. Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a029249. doi: 10.1101/cshperspect.a029249. Cold Spring Harb Perspect Med. 2019. PMID: 29440323 Free PMC article. Review.

• Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis.

  Song JY, Griffin JD, Larson NR, Christopher MA, Middaugh CR, Berkland CJ. Song JY, et al. Front Immunol. 2021 Jan 18;11:603029. doi: 10.3389/fimmu.2020.603029. eCollection 2020. Front Immunol. 2021. PMID: 33537031 Free PMC article.

• Glatiramer acetate persists at the injection site and draining lymph nodes via electrostatically-induced aggregation.

  Song JY, Larson NR, Thati S, Torres-Vazquez I, Martinez-Rivera N, Subelzu NJ, Leon MA, Rosa-Molinar E, Schöneich C, Forrest ML, Middaugh CR, Berkland CJ. Song JY, et al. J Control Release. 2019 Jan 10;293:36-47. doi: 10.1016/j.jconrel.2018.11.007. Epub 2018 Nov 7. J Control Release. 2019. PMID: 30414463 Free PMC article.

• Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes.

  Carpintero R, Brandt KJ, Gruaz L, Molnarfi N, Lalive PH, Burger D. Carpintero R, et al. Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17692-7. doi: 10.1073/pnas.1009443107. Epub 2010 Sep 27. Proc Natl Acad Sci U S A. 2010. PMID: 20876102 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program